D.O.D.

Entegrion Awarded $43.7 Million

Entegrion Awarded $43.7 Million to Bring Resusix™ to Market. Research Triangle Park, NC, October 4, 2011 – Entegrion announced today it has received a contract valued up to $43.7 Million from the Department of Defense. The RTP life sciences development company will apply the funding to the clinical development of Resusix™, its proprietary dehydrated pathogen-inactivated…

Read More